Shots: The approval is based on the P-III PEACHTREE trial to evaluate Xipere in 160 patients with macular edema associated with uveitis. The therapy is expected to be available in […]readmore
Tags : Clearside
Pharma
Bausch Health In-Licenses Clearside’s Xipere (triamcinolone acetonide suprachoroidal injectable suspension)
Shots: Clearside to receive ~$20M prior to launch including an up front and is eligible to receive commercial & regulatory milestones on approval of Xipere for an additional indication and […]readmore